Overview

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

Status:
Completed
Trial end date:
2020-11-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stanford University
Treatments:
Dacarbazine
Temozolomide